CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于检测不同方法制备 CD19 CAR-T 细胞的体内实验小鼠模型
英文原题：In vivo experimental mouse model to test CD19CAR T cells generated with different methods.
查看英文原题
In vivo experimental mouse model to test CD19CAR T cells generated with different methods.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞的临床前评估包括在尽可能接近真实世界条件下测试T细胞疗效和安全性的程序。疗效测试中的一个重要步骤是体内研究，最常使用免疫缺陷小鼠模型，将毒药和疗法都注射进去；即人类癌细胞系和基因修饰的人类T细胞。T细胞控制癌症进展的能力将提供有关CAR-T 细胞疗效的信息。我们在此提供一种使用经过验证的抗B细胞标志物CD19CAR和侵袭性淋巴瘤模型在体内测试CAR-T 细胞的方案。
展开英文摘要原文
Pre-clinical evaluation of CAR T cells includes procedures testing T-cell efficacy and safety in as close to real world conditions as possible. An important step in efficacy testing is the in vivo study, most often using immunodeficient murine models into which both the poison and the cure are injected; namely a human cancer cell line and genetically modified human T cells. The capacity of the T cells to control the cancer progression will provide information about the CAR T-cell efficacy.
We here provide a protocol to test CAR T cells in vivo using the validated anti-B-cell marker CD19CAR and an aggressive lymphoma model.
论文信息
- 作者
- Fåne A、Myhre MR、Inderberg EM、Wälchli S
- 第一作者单位
- Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.Norway
- 通讯作者单位
- Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway. Electronic address: sebastien.walchli@rr-research.no.Norway
- 文献类型
- 非美国政府资助研究
- 期刊
- Methods in cell biology2022
- 原文标识
- PubMed 35152992 · DOI 10.1016/bs.mcb.2021.11.001